Iran Advances to 7th Place Globally in Regenerative Medicine with Six New ATMP Approvals
核心洞察
Iran has risen from 12th to 7th place globally in regenerative medicine following approval of six new Advanced Therapy Medicine Products (搜索) (ATMP) by regulatory authorities.
The approved products span cell therapy, tissue engineering, and CAR-T therapy (搜索), targeting critical conditions including vitiligo (搜索), graft-versus-host disease (搜索), cerebral palsy (搜索), burns, diabetic foot ulcers (搜索), osteoarthritis (搜索), and leukemia.
Iran now holds seven of the world's 148 licensed ATMP products, representing a dramatic increase from just one product available in March 2023 to seven by March 2025.
Iran has achieved a significant milestone in regenerative medicine, climbing from 12th to 7th place globally following regulatory approval of six new Advanced Therapy Medicine Products (搜索) (ATMP). This advancement positions the Islamic Republic among the world's top 10 countries in this cutting-edge medical field, with seven of the global total of 148 licensed ATMP products now originating from Iran.
Rapid Growth in Advanced Therapeutics
The transformation has been particularly striking in its speed. According to official statistics, Iran had only one licensed ATMP product available in March 2023, but this number has expanded to seven by March 2025. The six newly approved products were developed by researchers at Royan (搜索), an institution providing comprehensive services in regenerative medicine and cell therapy.
These Advanced Therapy Medicine Products (搜索) are medicines for human use based on genes, tissues, or cells, offering groundbreaking opportunities for treating disease and injury. The approved products cover three strategic therapeutic areas: cell therapy, tissue engineering, and chimeric antigen receptor (搜索) (CAR) T-cell therapy.
Addressing Critical Medical Needs
The newly approved therapies target a range of serious medical conditions that represent significant unmet needs in Iran's healthcare system. The products are designed to treat vitiligo (搜索), graft-versus-host disease (搜索) (GVHD), cerebral palsy (搜索) (CP), burns, diabetic foot ulcers (搜索), osteoarthritis (搜索), and B-cell acute lymphoblastic leukemia (搜索) (B-cell ALL).
According to Iran's Headquarters for Stem Cell and Biological Sciences (搜索), some of these therapies involve cutting-edge technology and demonstrate export potential, suggesting opportunities for international market expansion.
Infrastructure and Regulatory Development
The achievement reflects broader developments in Iran's regenerative medicine ecosystem. Key infrastructure improvements include the expansion of research and production facilities, the launch of the national supervised-use platform for advanced therapeutic products (IranATMP.com), and streamlined regulatory processes developed in collaboration with the Food and Drug Organization (搜索) and the Treatment Deputy of Iran's Ministry of Health.
The regulatory framework has been supported by innovative financing mechanisms, including specialized funds and corporate venture capital (CVC) tools designed to facilitate the continued production, commercialization, and development of both domestic and export markets for these products.
Global Context and Future Implications
The global landscape for advanced therapy medicinal products shows 148 approved products across 12 recognized regulatory organizations worldwide as of 2025. Iran's contribution of seven products places it in an exclusive group of countries leading this advanced medical sector.
Experts suggest that maintaining this trajectory could establish Iran as a regional hub for regenerative medicine, potentially facilitating the development of advanced treatments and the export of knowledge-based products. The achievement also contributes to reducing reliance on imported complex medical products while strengthening Iran's scientific standing in the West Asia region.
The development represents a significant contribution to Iran's knowledge-based economy and demonstrates the country's growing capabilities in advanced biotechnology and regenerative medicine research and development.